Alveolus Bio
  • About Us
  • Science
    • Our Science
    • Publications
  • Pipeline
  • Team
Select Page
Alveolus Bio’s Founder, Dr. Vivek Lal, to Present at BIO CEO & Investor Conference 

Alveolus Bio’s Founder, Dr. Vivek Lal, to Present at BIO CEO & Investor Conference 

by Alveolus Bio | Feb 11, 2022 | Company News

Birmingham, February 11, 2022 – Alveolus Bio announced today Dr. Vivek Lal, Founder & Chief Executive Officer, will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually...

Recent Posts

  • Alveolus Bio’s Founder, Dr. Vivek Lal, to Present at BIO CEO & Investor Conference 
  • Alveolus Bio to Present at Biotech Showcase 2022
  • Neutrophilic inflammation during lung development disrupts elastin assembly and predisposes adult mice to COPD (2021)
  • Early airway microbial metagenomic and metabolomic signatures are associated with development of severe bronchopulmonary dysplasia (2018)
  • The Airway Microbiome at Birth (2016)

Recent Comments

    1500 1st Ave N, Birmingham, AL 35203

    1 Broadway, Cambridge, MA 02142

    • Follow

    © Alveolus Bio Inc 2022

    Alveolus Bio is a team of scientists, physicians, and innovators pioneering breakthrough FDA-approved therapeutics for lung diseases. Our pipeline includes preclinical phase live biotherapeutics for Chronic Obstructive Pulmonary Disease (COPD), Bronchopulmonary Dysplasia, Pulmonary fibrosis, Lung Injury Secondary to Viral Illness, Neutrophilic Asthma, and earlier stage programs, including Pulmonary Arterial Hypertension (PAH), Acute Respiratory Distress Syndrome, and Cystic Fibrosis (CF).

    ©Alveolus Bio Inc. 2022 | Please click here to access our Financial Conflict of Interest Policy